Regular physical activity not only improves the exercise capacity of the skeletal muscle performing the contractions, but it is beneficial for the whole body. An extensive search for Bexercise factors^mediating these beneficial effects has been going on for decades. Particularly skeletal muscle tissue has been investigated as a source of circulating exercise factors, and several myokines have been identified. However, exercise also has an impact on other tissues. The liver is interposed between energy storing and energy utilising tissues and is highly active during exercise, maintaining energy homeostasis. Recently, a novel group of exercise factors-termed hepatokines-has emerged. These proteins (fibroblast growth factor 21, follistatin, angiopoietin-like protein 4, heat shock protein 72, insulin-like growth factor binding protein 1) are released from the liver and increased in the bloodstream during or in the recovery after an exercise bout. In this narrative review, we evaluate this new group of exercise factors focusing on the regulation and potential function in exercise metabolism and adaptations. These hepatokines may convey some of the beneficial whole-body effects of exercise that could ameliorate metabolic diseases, such as obesity or type 2 diabetes.
Introduction
Health benefits from exercise have long been acknowledged, and regular physical activity is recommended as therapeutic intervention to prevent and treat a range of chronic disorders, including obesity, insulin resistance and type 2 diabetes [1] . Exercise initiates several transcriptional and (post)translational mechanisms in skeletal muscle, which increases the capacity and efficiency for fuel uptake and utilisation, thus improving whole-body energy metabolism [2] . However, several tissues respond to physical activity, for which reason the orchestration of tissue-specific functions is crucial, bringing the concept of circulating exercise factors into play which could mediate the cross-talk. To regulate energy metabolism, various tissues produce signalling molecules to communicate between energy storing and energy utilising tissues. With the discovery of leptin [3] as a signalling molecule secreted by the adipose tissue, the term Badipokine^was coined. Transferring the concept of adipokines to the energy utilising This article is part of the special issue on Exercise Physiology: future opportunities and challenges in Pflügers Archiv * Cora Weigert cora.weigert@med.uni-tuebingen.de * Peter Plomgaard plomgaard@dadlnet.dk skeletal muscle tissue, interleukin (IL)-6 was the first musclederived signalling molecule to be termed a myokine [4] , even though myostatin (growth differentiation factor (GDF)-8) had been classified as a muscle-derived hormone years before [5] . Since then, several endocrine functions have been attributed to the myokines secreted by the working muscle including regulation of body weight and insulin sensitivity, as well as tumour suppression and maintenance of cognitive functions [6] . The liver is a central organ in energy metabolism, interposed between energy storage and utilisation and as such, challenged both during physiological (exercise, fasting, food intake) and pathophysiological (metabolic syndrome, diabetes, obesity, cachexia) conditions. In analogy to adipo-and myokines, signalling molecules exclusively or predominantly produced by the liver and secreted into the bloodstream that impact extrahepatic tissues/organs [7] have been termed Bhepatokines^. During the last decade, hepatokines have principally been studied in the context of metabolic diseases [8] . Prominent examples are fetuin-A (also known as α-2-Heremans-Schmid glycoprotein) and selenoprotein P (SeP), which are linked to insulin resistance [9, 10] . In contrast, fibroblast growth factor (FGF)21 has the potential to improve glucose homeostasis and dyslipidemia [11] . In the present narrative review, we summarise and discuss hepatokines in relation to acute exercise and physical training as well as their potential role in energy homeostasis and metabolic adaptations.
The role of the liver in exercise metabolism
The liver plays a pivotal role in exercise metabolism when the energy balance becomes negative and substrates need to be mobilised from storage or synthesised. Hepatic glucose production is increased via breakdown of glycogen as well as enhanced de novo synthesis of glucose from lactate, glycerol and amino acids. The relative contribution of the hepatosplanchnic bed to the whole-body uptake of free fatty acids (FFA) decreases during exercise, but the absolute uptake increases, and FFA are oxidised to provide energy for ATPconsuming biochemical processes [12] . After prolonged exercise, excess FFA are also re-esterified to triglycerides, and elevated hepatic triglyceride content can be observed [13, 14] .
A major regulator of hepatic metabolism during exercise is a change in the glucagon-to-insulin ratio, which increases due to both an increase in glucagon and a decrease in insulin in the circulation. Exercise studies in rodents demonstrate a fall in hepatic energy charge with increased production of AMP, which is considered to trigger glycogen mobilisation [15] and to stimulate oxidation of fatty acids via activation of AMPK. The increase in circulating catecholamines during high intensity exercise has been suggested to stimulate hepatic glucose output [16] , but hepatic adrenergic blockade in dogs did not reduce glucose delivery from the liver [17] , and thus, the contribution of the adrenergic system is not completely clear. Growth hormone (GH) and cortisol are both elevated by exercise and may partially contribute to the adaptation of hepatic metabolism [18] . The increased metabolic activity of the liver during exercise is reflected by a higher hepatosplanchnic oxygen uptake. During moderate exercise, hepatic blood flow is unchanged or only slightly reduced [19, 20] while hepato-splanchnic oxygen uptake is upregulated more than twofold [21] , presumably due to high levels of oxygen extraction [22] . Of note, exercising with very high intensity can markedly reduce hepato-splanchnic blood flow [23, 24] , which may compromise hepatic metabolism [23] .
Searching for potential exercise-regulated hepatokines-candidates from mouse microarray data Upregulation of gene expression is one mechanistic pathway which can lead to increased production and release of adipokines, hepatokines and myokines. One bout of acute exercise increases the transcript and protein levels of several myokines in the contracting muscle [25, 26] . Compared with skeletal muscle, even more transcripts in the liver of mice showed pronounced alterations immediately after a nonexhaustive treadmill exercise [27, 28] . Filtering these transcripts for genes encoding potentially secreted proteins revealed 55 upregulated genes after exercise and 29 transcripts with reduced abundance (Table 1 ). The list of regulated transcripts is dominated by cytokines, chemokines and components of the extracellular matrix. Insulin-like growth factor-binding protein (IGFBP)1 showed the highest change with significant signal intensities already in sedentary mice. FGF21 was also strongly increased by acute exercise while being almost undetectable in livers of sedentary mice. The exercise-dependent regulation and secretion of both factors has been validated in mice and humans as described below in further detail. Additional hepatic transcripts regulated by acute exercise in our transcriptomics study, which are already known as liver-derived secreted factors are follistatin, angiopoietin-like 4 protein (ANGPTL4) and inhibin E.
Several of the transcripts listed in Table 1 may contribute to changes in the systemic concentration and may be involved in intrahepatic adaptations to exercise, but will not be discussed further due to their wide tissue distribution. Moreover, a transcriptomics approach cannot cover all exercise-regulated hepatokines because an increased release of proteins is not necessarily reflected in an elevated transcript level. For instance, post-translational regulation or an enhanced secretion of existing protein pools, which is not reflected on the transcriptional level, has been reported for two myokines, IL6 and secreted protein acidic and rich in cysteine (SPARC) [29, 30] .
In the following paragraphs, we will focus on hepatokines with evidence for transcriptional regulation by exercise and hepatic release into the bloodstream. Of note, elevated protein abundance in hepatic tissue accompanied by increased plasma concentration is a good hint for an actual release from the liver into the circulation, but the best evidence in humans is a net efflux from the hepato-splanchnic bed, which can be analysed as arterial-to-hepatic vein difference. This release from the hepato-splanchnic bed has been reported for FGF21, follistatin, ANGPTL4 and heat shock protein (HSP) 72 in relation to an acute exercise bout [19, [31] [32] [33] and in the resting condition for IGFBP1 [34] . Transcripts with at least twofold regulation and secreted protein annotation (SL-0243, Uniprot) or annotation as extracellular matrix protein (ECM; GO:0031012) are shown. Mice ran 60 min at 14 m/min and 14 o uphill inclination on an electric treadmill and livers were obtained immediately after the run. Sedentary mice remained in their cages. Sed, run: signal intensity of transcripts on Illumina mouseRef-8 v1.0 Expression bead chip array (Illumina, San Diego, CA, USA) and respective Swissprot accession number. Experimental conditions are described in reference [27] Hepatokines in humans FGF21 FGF21 has emerged as a novel metabolic regulator [35] , which is preferentially expressed in the liver [36] . The hepatic origin of circulating FGF21 has elegantly been demonstrated in mice, where liver-specific knockout of FGF21 results in the absence of circulating FGF21 [37] . In humans, FGF21 is released from the hepato-splanchnic bed both after an overnight fast and during an acute bout of exercise [31] , supporting that FGF21 is a liver-derived factor both in mouse and man. In humans, circulating FGF21 is increased after a prolonged fast [38, 39] , exercise [40] , in type 2 diabetes [41] , steatosis [42] , non-alcoholic steatohepatitis [42] , obesity [42] and during critical illness [43] . Several mechanisms have been suggested for the regulation of FGF21, where the predominant one both in vitro and in vivo in mice is PPARα activation, which leads to increased FGF21 expression [44, 45] . In humans, 2 weeks' treatment with PPARα and β, but not γ agonists, increases circulating FGF21 [46] , which is in line with the fact that elevation of FFA-the endogenous agonist of PPAR α and β-for 4 h by infusion gives rise to an increase in plasma FGF21 [47] . The kinetics and the low magnitude of the FGF21 response to either PPAR activation or FFA infusion for 4 h [46, 47] are not consistent with the observation that FGF21 increases rapidly after an acute bout of exercise with a higher magnitude (exercise 2-to 3-fold versus 1.3-fold with PPAR or FFA activation), indicating that other regulatory mechanisms may exist.
The most powerful hormonal signal to induce an increase in circulating FGF21 is glucagon, where a 2.5-fold increase can be demonstrated [48] . Intriguingly, insulin has an inhibitory effect, and inducing an increased glucagon-to-insulin ratio in healthy males increases FGF21 with a similar magnitude and kinetic as during exercise [31] . Thus, the glucagon-toinsulin ratio is much more powerful in stimulating hepatic FGF21 secretion than activating PPAR, either pharmacologically or by FFA. During physical exercise, an increase in the glucagon-to-insulin ratio is crucial, as prevention of an increase in the glucagon-to-insulin ratio during an exercise bout blunts the exercise-induced increase in FGF21 [49] . An impaired exercise-induced FGF21 response has been reported both in obesity associated with insulin resistance [50] and in type 2 diabetes [49] . However, obesity per se does not impair exercise-induced FGF21 [51] . Although conjectural, insulin resistance seems to be the factor impairing the exerciseinduced FGF21 as recently reviewed [52] .
The relation of FGF21 to metabolism is not only reflected by its regulation, but indeed by its actions (Fig. 1) . FGF21 administered to mice [35] and humans [53] has beneficial effects on energy metabolism. Insulin-resistant mice treated with FGF21 reduce body weight and blood glucose concentrations [35] , and similarly, patients with type 2 diabetes treated with an FGF21 analogue experience weight loss and reduced fasting glucose levels after 2 weeks of treatment [53] . Adenoviral gene transfer to the liver of obese mice causes a reduction in weight gain, adipose tissue hypertrophy, hepatosteatosis and inflammation [54] . Moreover, this FGF21 gene therapy prevents insulin resistance associated with aging, while a FGF21 induced bone loss as potential adverse effect of FGF21 overexpression [55] was not observed. Liver, adipose tissue and brain are considered the most important sites of FGF21 action. Rodent studies in particular demonstrate that FGF21 mediates increased fatty acid oxidation and decreased lipogenesis in the liver [44, 45] as well as increased glucose uptake in adipose tissue-an effect mainly accounted for by brown adipocytes [56] . Human studies support a central regulation of food intake and reduction in sugar consumption by FGF21 [57, 58] and increased production of adiponectin [53, 59] . As FGF21 holds strong promise as a therapeutic target, exercise-induced FGF21 could be one of the molecular links that mediates the beneficial effects of exercise to the wholebody level. This is supported by the impaired exercise adaptations in FGF21-deficient mice, which fail to improve glucose tolerance and to reduce hepatic triglyceride content compared to wildtype mice under the same high-fat diet [60] .
Follistatin
The liver has recently been identified as the source of circulating follistatin [32] . Particularly during the first hours after an exercise bout, circulating follistatin is increased five-to sevenfold [32, 51, 61, 62] . Examination of various tissues in mice revealed that the liver exhibits a marked increase in follistatin mRNA expression immediately after an acute exercise bout [61] , which is supported by the observation in humans that follistatin is released from the hepatosplanchnic bed in the recovery state after an exercise bout [32] . Collectively, these data strongly suggest that the liver is the organ mainly accounting for circulating follistatin.
The initial perception was that circulating follistatin is a result of spill-over from auto-or paracrine processes, yet follistatin increases with prolonged fast [63] , pregnancy [64] , type 2 diabetes [65] and critical illness [66, 67] . A mutual feature of these conditions is an increase in the glucagon-toinsulin ratio as previously summarised [68] . Examining the regulation of exercise-induced follistatin revealed that the glucagon-to-insulin ratio is important for the increase in follistatin after exercise [49] . Thus, the regulation of circulating follistatin is clearly linked to energy metabolism. Additional stimuli must exist, as blunting the increase in the glucagon-to-insulin ratio during an exercise bout only reduces the exercise-induced rise in follistatin levels by 50%. Moreover, exercise-induced follistatin is impaired by insulin resistance [49] but not by obesity per se [51] .
Follistatin has primarily been investigated as a TGF-β modulating protein due to its inhibition of activins and GDFs, but follistatin is a pluripotent molecule and several target tissues have been suggested (Fig. 1) . Firstly, follistatin acts on the endocrine pancreas modulating both insulin and glucagon secretion, which suggests a feedback regulation [32] . Secondly, follistatin may have a role in regulating muscle hypertrophy where follistatin acts in concert with myostatin [69] , insulin and IGF [70] as well as testosterone [71] . In vivo follistatin treatment induces muscle hypertrophy in mice [72] and nonhuman primates [73] , and follistatin gene therapy has been tested in a phase 1/2a study in patients with Becker's muscle dystrophy, where an improvement in muscle function was observed [74] . Thirdly, a recent study demonstrated that chronic activation of Forkhead box (Fox)O1 drives hepatic expression of follistatin, which leads to impaired insulin sensitivity in adipose tissue, potentiation of hepatic glucose production and severe glucose intolerance in mice [75, 76] . Even though highly speculative, a lack of insulin suppression of adipose tissue lipolysis and hepatic glucose production might be of advantage during endurance exercise and the early recovery phase. More studies are needed to understand the physiological role of follistatin as exercise-regulated hepatokine. However, follistatin is a pluripotent molecule and could function as a means of communication from the liver to the endocrine pancreas, skeletal muscle or adipose tissue, acting as a link between energy metabolism and tissue growth and differentiation.
ANGPTL4
Like follistatin, plasma ANGPTL4 increases during exercise and in the recovery phase in healthy subjects [77] . ANGPTL4 was identified in mice as Bfasting-induced adipose factor^in both adipose tissue [78] and liver [79] . In humans, ANGPTL4 is highly expressed in the liver followed by the pericardium, whereas adipose and skeletal muscle tissue expression is low [80] . Skeletal muscle has been suggested as a source of elevated plasma levels of ANGPTL4 in response to exercise [77, 81] . However, when ANGPTL4 release is measured by arterial-to-venous differences over both a resting and an exercising leg, no contribution of ANGPTL4 to the systemic circulation can be detected [33] . In contrast, a release of ANGPTL4 can be detected from the hepato-splanchnic bed during exercise with no release at rest [33] . Thus, in humans, exercise-induced ANGPTL4 is released in to the circulation via the hepato-splanchnic bed from the liver while other tissues contribute to the systemic ANGPTL4 level in the resting state. Induction of ANGPTL4 in adipose tissue during fasting is ascribed to PPARα activation [78] , but other PPARs were also found to have regulatory effects on ANGPTL4 expression [82] , which has been supported by promoter analysis [83] . These findings are in line with ANGPTL4 being a fastinginduced protein as FFA, which are the ligands of PPARs, increase during fasting [84] . A common denominator of fasting and exercise is the increase in the glucagon-to-insulin ratio. Indeed, an experimentally induced increase in the glucagon-to-insulin ratio in healthy subjects resting in bed increases systemic levels of ANGPTL4, and blunting the increase in the glucagon-to-insulin ratio in healthy males during a bout of bicycle exercise abolishes the exercise-induced ANGPTL4 increase [33] . Taken together, these in vivo observations in humans demonstrate that the glucagon-to-insulin ratio is pivotal for the induction of ANGPTL4 during physical exercise.
The function of ANGPTL4 has been studied in vivo and in vitro, where it acts as an inhibitor of lipoprotein lipase (LPL) [85] (Fig. 1) . LPL mediates the degradation of lipoprotein triglycerides into FFA in various tissues [86] and is increased in skeletal muscle tissue by fasting [87] . In line with the observation that ANGPTL4 is an inhibitor of LPL activity, circulating triglyceride levels are decreased in mice lacking ANGPTL4 [88] and increased in mice overexpressing ANGPTL4 [85, 88] . Population-based studies in humans have revealed that loss-offunction mutations in ANGPTL4 are associated with low levels of triglycerides [80, 89] . As ANGPTL4 is an inhibitor of LPL, it seems paradoxical that ANGPTL4 increases under the exact conditions where an increased breakdown of triglycerides is important-as it is the case during exercise and fasting. Based on tissue-specific overexpression models, ANGPTL4 has also been suggested to play a role in lipid partitioning and tissue-specific uptake or release of FFA [90, 91] and to improve glucose metabolism [92] . In contrast, a recent study linked the genetic inactivation or loss of ANGPTL4 to a reduced risk of type 2 diabetes and improvement in glucose homeostasis [93] . An additional function attributed to ANGPTL4 is supporting angiogenesis [94] , while recent studies on the regulation of pancreatic α-cells are inconsistent [95, 96] . ANGPTL4-induced inhibition of LPL activity is due to direct protein-protein interaction [90, 97] , and it is unclear whether an ANGPTL4 receptor exists to mediate other effects attributed to this protein. Nevertheless, the acute regulation of plasma ANGPTL4 levels may suggest an endocrine role as a liver-derived signal to the peripheral tissues.
A pathway jointly regulating the hepatic FGF21, follistatin and ANGPTL4 response to exercise A rise in the glucagon-to-insulin ratio increases the plasma concentration of FGF21, follistatin and ANGPTL4 in vivo in humans [31] [32] [33] . Stimulation of hepatocytes with glucagon activates the adenylyl cyclase and intracellular cAMP increases [98] , while cAMP levels are reduced by insulin via activation of phosphodiesterase (PDE) [98] . Thus, the glucagon-to-insulin ratio sensed by the liver determines cAMP levels within the hepatocyte. Both glucagon and adrenalin can stimulate the adenylyl cyclase during exercise; however, glucagon seems to be the determinant of cAMP levels during exercise [99] . FoxO transcription factors appear to play an important role in the enhanced hepatic transcription of FGF21, follistatin and ANGPTL4. Exercise does not only induce hepatic cAMP levels, but also activates AMPK and JNK in the liver [27, 100] and all these pathways activate FoxO [101] . The inhibitory effect of insulin on the transcription of these hepatokines may be mediated by the PI3K/PKB pathway, which leads to inactivation of FoxO1 [76] .
In addition, PPARs are established regulators of FGF21 and ANGPTL4 expression, but the contribution of this pathway to exercise-dependent hepatokine production has not been fully clarified. Prevention of the increase in the glucagon-to-insulin ratio by somatostatin infusion during exercise also blocked the increase in plasma FFA [49] , and thus, a contribution of elevated FFA to the increase in hepatokines cannot be excluded. Interestingly, elevation of cAMP levels in hepatocytes directly increases ANGPTL4 mRNA levels [33] , and the cAMP/PKA pathway can regulate the transcriptional activity of PPARs [102] . Collectively, a molecular pathway exists for hepatokine production where secretion is stimulated via cAMP, and inhibition occurs via the insulin-regulated enzymes PDE and PKB, as summarised in Fig. 2 . This regulation by the glucagon-to-insulin ratio suggests that systemic levels of these hepatokines are influenced by hepatic insulin resistance, and reduction in insulin action can result in less inhibition of hepatokine secretion. As discussed above, elevated circulating levels of FGF21 [41] , ANGPTL4 [103] and follistatin [65] have been demonstrated in patients with type 2 diabetes.
HSP72
In humans, HSP72 increases in the circulation during an acute bout of exercise [104] . Skeletal muscle, liver and brain have been suggested to be the tissues responsible for exerciseinduced HSP72 release [105, 106] . Measurement of arterialto-venous differences in healthy humans during exercise demonstrates a release of HSP72 from the hepato-splanchnic bed, while no release is detected over the exercising leg or at rest [19] . In addition, the brain releases HSP72 to the circulation during exercise [105] . Taken together, HSP72 is an exerciseinduced hepatokine; however, contributions from other tissues add to the increase in HSP72 observed with exercise.
The regulation of HSP72 during exercise has not been completely elucidated. Different from what its name suggests, heat per se only influences HSP72 induction to a minor degree during exercise in humans [107] . In rats, stress-induced circulating HSP72 is not affected by hypophysectomy or adrenalectomy, which rules out growth hormone, epinephrine and cortisol as major stimulatory signals [108] . However, phenylephrine increases plasma HSP72, and blocking of α1-adrenergic receptor by prazosin blunts stress-induced HSP72, whereas a β-selective antagonist (propranolol) has no effect, which collectively suggests that norepinephrine is a stimulating signal [108] . Interestingly, ingestion of glucose during exercise completely blunts hepato-splanchnic release of HSP72, suggesting a role for the glucoregulatory hormones insulin and glucagon [109] . However, no regulation of liver HSP72 mRNA is observed with a 48-h fast in rats [110] . Thus, the cross-talk between the adrenergic and glucose-induced hormones still needs to be elucidated.
The roles of HSP72 seem to be diverse and related to whether it is located intra-or extracellularly [111] . Overexpression of HSP72 protects against heatstroke [112] , which is in line with a muscle-specific overexpression protecting against exercise-induced skeletal muscle damage [113] and preserving muscle function [114] (Fig. 1) . Interestingly, overexpression of HSP72 in cardiac and skeletal muscle tissue increases exercise performance, oxidative capacity and mitochondrial content and also protects against obesity-induced insulin resistance [115] , suggesting a role in energy metabolism. However, the contribution of liverderived HSP72 to the abovementioned effects has not been validated yet. Since HSP72 also regulates hepatic fatty acid oxidation and maintenance of mitochondrial function in the liver, a paracrine function of exercise-induced HSP72 can be considered as well [116] .
IGF-1 and IGFBP1
Both GH and IGF1 levels increase at an early stage during an exercise bout in the circulation [117, 118] . During exercise, IGF is not released solely from the liver, as a contribution from the exercising leg has also been demonstrated [119] . Plasma IGFBP1 increases during prolonged exercise in humans [120] , and hepatic IGFBP1 mRNA and protein levels are strongly upregulated during acute exercise in mice (Table 1 ) [27] . The increase is clearly linked to the hepatic energy state and is regulated by hepatic glycogen depletion [121] and thus dependent on the duration of exercise [27] . FoxO proteins are important regulators of IGFBP1 transcription, which may be the link between tissue glycogen content and regulation of IGFBP1 production during exercise (Fig. 2) [122] .
Circulating IGFBPs regulate the bioavailability of IGF1, but the physiological function of elevated plasma levels of IGFBP1 during prolonged exercise remains elusive. Exercise also induces intrahepatic IGFBP1 protein accumulation in mice [27] , raising the possibility that this increase promotes an anti-apoptotic effect by interfering with the p53 tumour suppressor protein, which is also elevated in the liver after acute exercise [123] . 
GDF15
GDF15 is a hepatokine candidate based on its upregulation in the liver of mice during an acute bout of exercise, as shown in Table 1 . This notion is strengthened by the observation that GDF15 is strongly induced by fasting in mice [124] , which supports the idea that energy depletion regulates hepatic GDF15 mRNA levels. GDF15 protein has recently been shown to increase in the circulation in response to an acute bout of exercise [125] . In relation to exercise, GDF15 was initially thought to be a myokine, but no release could be detected from an exercising leg [125] . In similarity with FGF21, follistatin and ANGPTL4, increased levels of circulating GDF15 are associated with insulin resistance [126] . The receptor for GDF15 has been identified to be the orphan receptor GDNF family receptor alpha like (GFRAL), which is expressed in the brain and is involved in the regulation of food intake [127, 128] . Whether GDF15 is released from the liver and how it is regulated during an acute bout of exercise still needs to be addressed.
Inhibin βE
Inhibin βE is one of the hepatokine candidates with a downregulation of its mRNA after acute exercise (Table 1) . It was recently classified as hepatokine, which is associated with insulin resistance [129] . Human liver biopsies from insulinresistant subjects have increased expression levels of inhibin βE mRNA, and knock-down of inhibin βE in an obese mouse model improves fatty acid oxidation. The influence of acute exercise and regular physical activity on circulating inhibin βE needs to be investigated. Reduced levels of circulating inhibin βE may be involved in mediating the beneficial effects of exercise on glucose tolerance and insulin sensitivity.
A role for the hepatokine selenoprotein P in exercise adaption
The systemic level of a hepatokine may alter the response to exercise even if it is not regulated by physical activity. The plasma concentration of the hepatokine selenoprotein P (SeP) has been linked to the training responsiveness in VO 2 max [130] in humans and mice. SeP is produced mainly in the liver and functions as a transport protein supplying selenium to extrahepatic tissues [131] . Hepatic SeP transcript levels are not altered by acute exercise or training in mice, and plasma SeP concentrations are unchanged after 8 weeks of aerobic exercise training in humans [130] . However, SeP-deficient mice on a high-fat diet have enhanced responses in muscle PGC1α mRNA levels, mitochondrial content and exercise endurance after training when compared to wildtype mice [130] . Further data provide evidence for a function of liverderived SeP as regulator of exercise-induced reactive oxygen species (ROS) production in skeletal muscle [130] . Absence or low concentrations of SeP allow higher levels of ROS, which are considered to trigger mitochondrial adaptations [132] in response to exercise (Fig. 1) . SeP may also modulate the effects of exercise in humans, since pre-training SeP plasma levels are inversely associated with the improvement in VO 2 max in middle-aged humans without diabetes and obesity [130] .
Conclusion and outlook
During and particularly after an exercise bout, the liver secretes potential exercise factors. The exercise-induced hepatokines are regulated by several stimuli where the glucagon-to-insulin ratio seems to be most relevant for FGF21, follistatin and ANGPTL4. These factors are all elevated with insulin resistance, while the response of FGF21 and follistatin to an acute bout of exercise appears to be impaired in subjects with insulin resistance. Obesity per se does not affect the exercise-induced response of these hepatokines. This conjectures that FGF21 and follistatin may discriminate between distinct effects of steatosis and insulin resistance of the liver. Another relevant question is whether regular physical activity alters the concentration of circulating hepatokines associated with insulin resistance thereby contributing to the improvement of metabolic disorders.
In conclusion, the liver is not merely an organ receiving humoral stimuli; it is also communicating to extrahepatic tissues such as the adipose tissue and skeletal muscle. Research is now beginning to unravel the physiological role of circulating hepatokines in the adaptation to physical exercise and in the beneficial effect of exercise on whole-body metabolic homeostasis. 
